@article{
 title = {A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence},
 type = {article},
 year = {2017},
 identifiers = {[object Object]},
 volume = {42},
 id = {71d87d9c-949b-3552-8388-e6862a46e323},
 created = {2017-12-22T22:16:20.251Z},
 file_attached = {false},
 profile_id = {8d59e387-d496-32ff-b1d5-5e8a974a8c7e},
 last_modified = {2019-10-14T10:57:14.684Z},
 read = {false},
 starred = {false},
 authored = {true},
 confirmed = {false},
 hidden = {false},
 folder_uuids = {9e7288a2-1de2-4cbd-b303-b32152c3437a,b514a1e1-5104-46d3-b6e1-5c6cf801c147},
 private_publication = {false},
 abstract = {© 2017 American College of Neuropsychopharmacology. All rights reserved. Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM-IV alcohol dependence were recruited across four sites. Participants received double-blind ABT-436 or placebo, and a computerized behavioral intervention. ABT-436 was titrated to 800 mg/day during weeks 2-12. Although the primary outcome, percentage of heavy drinking days, was lower in participants receiving ABT-436 compared with placebo, this difference was not statistically significant (31.3 vs 37.6, respectively; p=0.172; d=0.20). However, participants receiving ABT-436 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, respectively; p=0.037; d=0.31). No significant differences were found between treatment groups on any other measures of drinking, alcohol craving, or alcohol-related consequences. Smokers receiving ABT-436 smoked significantly fewer cigarettes per week than those receiving placebo (p=0.046). ABT-436 was well tolerated, with di arrhea (mild-to-moderate severity) being the most common side effect. In subgroup analyses, participants with relatively higher baseline levels of stress responded better to ABT-436 than placebo on select drinking outcomes, suggesting there may be value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent patients.},
 bibtype = {article},
 author = {Ryan, M.L. and Falk, D.E. and Fertig, J.B. and Rendenbach-Mueller, B. and Katz, D.A. and Tracy, K.A. and Strain, E.C. and Dunn, K.E. and Kampman, K. and Mahoney, E. and Ciraulo, D.A. and Sickles-Colaneri, L. and Ait-Daoud, N. and Johnson, B.A. and Ransom, J. and Scott, C. and Koob, G.F. and Litten, R.Z.},
 journal = {Neuropsychopharmacology},
 number = {5}
}

{"_id":"S2qiRCWqRDao2fzfD","bibbaseid":"ryan-falk-fertig-rendenbachmueller-katz-tracy-strain-dunn-etal-aphase2doubleblindplacebocontrolledrandomizedtrialassessingtheefficacyofabt436anovelv1breceptorantagonistforalcoholdependence-2017","authorIDs":["5d841b093d1af8db010001da","5e55e7f7c2c8a2df0100007c","5e55eac4c2c8a2df0100009a","5e56800cdf3460df010001e1","5e572a80bf9f82de01000002","5e57b645041daade010001d6","5e587f411d5966df0100001c","izHbHddmSyS8p6QbK"],"author_short":["Ryan, M.","Falk, D.","Fertig, J.","Rendenbach-Mueller, B.","Katz, D.","Tracy, K.","Strain, E.","Dunn, K.","Kampman, K.","Mahoney, E.","Ciraulo, D.","Sickles-Colaneri, L.","Ait-Daoud, N.","Johnson, B.","Ransom, J.","Scott, C.","Koob, G.","Litten, R."],"bibdata":{"title":"A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence","type":"article","year":"2017","identifiers":"[object Object]","volume":"42","id":"71d87d9c-949b-3552-8388-e6862a46e323","created":"2017-12-22T22:16:20.251Z","file_attached":false,"profile_id":"8d59e387-d496-32ff-b1d5-5e8a974a8c7e","last_modified":"2019-10-14T10:57:14.684Z","read":false,"starred":false,"authored":"true","confirmed":false,"hidden":false,"folder_uuids":"9e7288a2-1de2-4cbd-b303-b32152c3437a,b514a1e1-5104-46d3-b6e1-5c6cf801c147","private_publication":false,"abstract":"© 2017 American College of Neuropsychopharmacology. All rights reserved. Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM-IV alcohol dependence were recruited across four sites. Participants received double-blind ABT-436 or placebo, and a computerized behavioral intervention. ABT-436 was titrated to 800 mg/day during weeks 2-12. Although the primary outcome, percentage of heavy drinking days, was lower in participants receiving ABT-436 compared with placebo, this difference was not statistically significant (31.3 vs 37.6, respectively; p=0.172; d=0.20). However, participants receiving ABT-436 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, respectively; p=0.037; d=0.31). No significant differences were found between treatment groups on any other measures of drinking, alcohol craving, or alcohol-related consequences. Smokers receiving ABT-436 smoked significantly fewer cigarettes per week than those receiving placebo (p=0.046). ABT-436 was well tolerated, with di arrhea (mild-to-moderate severity) being the most common side effect. In subgroup analyses, participants with relatively higher baseline levels of stress responded better to ABT-436 than placebo on select drinking outcomes, suggesting there may be value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent patients.","bibtype":"article","author":"Ryan, M.L. and Falk, D.E. and Fertig, J.B. and Rendenbach-Mueller, B. and Katz, D.A. and Tracy, K.A. and Strain, E.C. and Dunn, K.E. and Kampman, K. and Mahoney, E. and Ciraulo, D.A. and Sickles-Colaneri, L. and Ait-Daoud, N. and Johnson, B.A. and Ransom, J. and Scott, C. and Koob, G.F. and Litten, R.Z.","journal":"Neuropsychopharmacology","number":"5","bibtex":"@article{\n title = {A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence},\n type = {article},\n year = {2017},\n identifiers = {[object Object]},\n volume = {42},\n id = {71d87d9c-949b-3552-8388-e6862a46e323},\n created = {2017-12-22T22:16:20.251Z},\n file_attached = {false},\n profile_id = {8d59e387-d496-32ff-b1d5-5e8a974a8c7e},\n last_modified = {2019-10-14T10:57:14.684Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {false},\n hidden = {false},\n folder_uuids = {9e7288a2-1de2-4cbd-b303-b32152c3437a,b514a1e1-5104-46d3-b6e1-5c6cf801c147},\n private_publication = {false},\n abstract = {© 2017 American College of Neuropsychopharmacology. All rights reserved. Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM-IV alcohol dependence were recruited across four sites. Participants received double-blind ABT-436 or placebo, and a computerized behavioral intervention. ABT-436 was titrated to 800 mg/day during weeks 2-12. Although the primary outcome, percentage of heavy drinking days, was lower in participants receiving ABT-436 compared with placebo, this difference was not statistically significant (31.3 vs 37.6, respectively; p=0.172; d=0.20). However, participants receiving ABT-436 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, respectively; p=0.037; d=0.31). No significant differences were found between treatment groups on any other measures of drinking, alcohol craving, or alcohol-related consequences. Smokers receiving ABT-436 smoked significantly fewer cigarettes per week than those receiving placebo (p=0.046). ABT-436 was well tolerated, with di arrhea (mild-to-moderate severity) being the most common side effect. In subgroup analyses, participants with relatively higher baseline levels of stress responded better to ABT-436 than placebo on select drinking outcomes, suggesting there may be value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent patients.},\n bibtype = {article},\n author = {Ryan, M.L. and Falk, D.E. and Fertig, J.B. and Rendenbach-Mueller, B. and Katz, D.A. and Tracy, K.A. and Strain, E.C. and Dunn, K.E. and Kampman, K. and Mahoney, E. and Ciraulo, D.A. and Sickles-Colaneri, L. and Ait-Daoud, N. and Johnson, B.A. and Ransom, J. and Scott, C. and Koob, G.F. and Litten, R.Z.},\n journal = {Neuropsychopharmacology},\n number = {5}\n}","author_short":["Ryan, M.","Falk, D.","Fertig, J.","Rendenbach-Mueller, B.","Katz, D.","Tracy, K.","Strain, E.","Dunn, K.","Kampman, K.","Mahoney, E.","Ciraulo, D.","Sickles-Colaneri, L.","Ait-Daoud, N.","Johnson, B.","Ransom, J.","Scott, C.","Koob, G.","Litten, R."],"bibbaseid":"ryan-falk-fertig-rendenbachmueller-katz-tracy-strain-dunn-etal-aphase2doubleblindplacebocontrolledrandomizedtrialassessingtheefficacyofabt436anovelv1breceptorantagonistforalcoholdependence-2017","role":"author","urls":{},"downloads":0},"bibtype":"article","creationDate":"2019-09-20T00:19:21.635Z","downloads":0,"keywords":[],"search_terms":["phase","double","blind","placebo","controlled","randomized","trial","assessing","efficacy","abt","436","novel","v1b","receptor","antagonist","alcohol","dependence","ryan","falk","fertig","rendenbach-mueller","katz","tracy","strain","dunn","kampman","mahoney","ciraulo","sickles-colaneri","ait-daoud","johnson","ransom","scott","koob","litten"],"title":"A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence","year":2017}